Evolution of a Promising PLCL Biodegradable In-Situ Nano-Depot for a Sustained Subcutaneous Delivery
This study strives toward spotting the light on a promising biodegradable poly-d,l- lactide-co-ε-caprolactone (PLCL) polymer, to develop an advantageous parenteral in situ nano-depot system (ISDN), with easy and economical manufacturing and low viscosity so no need of large painful syringes thus can be subcutaneously administered, to achieve a sustained controlled delivery of antidepressant drugs (e.g. fluoxetine hydrochloride). Evaluation of all prepared formulations exhibited, felicitous encapsulation efficiencies, nano-range size not exceeding 100nm, typical spherically shaped morphology, Newtonian flow behavior,prolonged controlled release profiles with minimal burst effect for 14 days, successfully sterilized by filtration with no signs of microbial growth for 2 weeks, positive stability for 3 months and a sustained in-vivo effect, reflected by an increased area under the curve (AUC) in contrast to the oral weekly marketed "Durazac". The study feedback revealed that PLCL ISNDs can elevate depressant-patient’s compliance including pediatrics, by sustaining antidepressant drugs (e.g. fluoxetine hydrochloride) release time for long periods and consequently reducing the dose regimen and the frequency of injections, thus eliminating undesirable antidepressant drugs terrible side effects that can reach suicidal thoughts.
Keywords - Biodegradable, Poly-d,l- Lactide-co-ε-Caprolactone, in Situ Depot, Nanoparticle, Sustained, Subcutaneous.